Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Unusually-High Trading Volume – Here’s Why

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw an uptick in trading volume on Wednesday . 302,588 shares changed hands during mid-day trading, an increase of 58% from the previous session’s volume of 191,400 shares.The stock last traded at $26.25 and had previously closed at $26.80.

Chugai Pharmaceutical Trading Down 2.2%

The company has a market cap of $86.22 billion, a P/E ratio of 32.75 and a beta of 0.63. The company’s fifty day moving average is $24.95 and its 200 day moving average is $24.09.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings data on Friday, October 24th. The company reported $0.23 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 20.63% and a net margin of 32.74%.The firm had revenue of $2.26 billion for the quarter. Analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.